The Latest
-
Here’s Why We’re Not Too Worried About Microbot Medical’s (NASDAQ:MBOT) Cash Burn Situation
-
Amgen defeats Novartis appeal over arthritis drug Enbrel’s patents
-
Virus Shot From Pfizer, BioNtech Shows Promise in Early Test
-
Markets open higher on positive Pfizer vaccine data